Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

October 3, 2013

Primary Completion Date

April 14, 2015

Study Completion Date

April 14, 2015

Conditions
Encephalopathy, Hypoxic-Ischemic
Interventions
DRUG

Clonidine (Duraclon®)

"Clonidine at dosing intervals of 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.~* 10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration~* 20% drop in HR from the infant's baseline, sustained for ≥30 min after administration~* HR ≤70/min, sustained for ≥30 min after administration"

Trial Locations (1)

21287

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
collaborator

University of Maryland

OTHER

lead

Johns Hopkins University

OTHER

NCT01862250 - Safety of Clonidine in Infants With Hypoxic Ischemic Encephalopathy During Therapeutic Hypothermia | Biotech Hunter | Biotech Hunter